Real-World Treatment Patterns for Metastatic Castration-Sensitive Prostate Cancer
Dec 19, 2023
More than half of patients with metastatic castration-sensitive prostate cancer (mCSPC) did not receiveandrogen deprivation therapy (ADT) plus docetaxel or ADT plus novel hormonal therapies as first-line treatment in 2019, even though these regimens are associated with improved survival compared to ADT alone, according to a study presented at the virtual 2021 ASCO Annual Meeting. These findings were presented by Daniel J. George, MD, FASCO, Duke Cancer Institute Center for Prostate and Urologic Cancers, Duke University, NC. “ADT has served as the standard of care for patients with mCSPC for decades, but recent clinical trials have shown that combining ADT with either docetaxel or novel hormonal therapy leads to improved survival compared to ADT alone,” explained Dr. George during his presentation.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…